The document is a corporate presentation by OSE Pharma, focusing on their investment thesis, market opportunities, and clinical development plans for their products OSE 2101 and OSE 1101. It outlines the clinical phases, market estimates, intellectual property, and business strategies for these products, targeting severe orphan lung diseases and cystic fibrosis. The presentation also includes financial projections, timelines, and management team details.
documents/EFTA01113739.pdf
{}